

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Miller Derek</u> _____ (Last) (First) (Middle) <u>ONE AMGEN CENTER DRIVE</u> _____ (Street) <u>THOUSAND CA 91320</u> _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>03/14/2022</u>	3. Issuer Name and Ticker or Trading Symbol <u>AMGEN INC [AMGN]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>SVP, Human Resources</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) _____ 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
<u>Common Stock</u>	<u>5,843⁽¹⁾⁽²⁾</u>	<u>D</u>	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
<u>Nqso (Right to Buy)</u>	<u>05/03/2018⁽³⁾</u>	<u>05/03/2026</u>	<u>Common Stock</u>	<u>1,524</u>	<u>156.35</u>	<u>D</u>	
<u>Nqso (Right to Buy)</u>	<u>05/01/2019⁽⁴⁾</u>	<u>05/02/2027</u>	<u>Common Stock</u>	<u>2,069</u>	<u>162.6</u>	<u>D</u>	
<u>Nqso (Right to Buy)</u>	<u>04/27/2020⁽⁵⁾</u>	<u>04/27/2028</u>	<u>Common Stock</u>	<u>1,821</u>	<u>177.46</u>	<u>D</u>	
<u>Nqso (Right to Buy)</u>	<u>05/03/2021⁽⁶⁾</u>	<u>05/03/2029</u>	<u>Common Stock</u>	<u>3,692</u>	<u>177.31</u>	<u>D</u>	
<u>Nqso (Right to Buy)</u>	<u>05/05/2022⁽⁷⁾</u>	<u>05/05/2030</u>	<u>Common Stock</u>	<u>3,365</u>	<u>236.36</u>	<u>D</u>	
<u>Nqso (Right to Buy)</u>	<u>04/30/2023⁽⁸⁾</u>	<u>04/30/2031</u>	<u>Common Stock</u>	<u>3,405</u>	<u>239.64</u>	<u>D</u>	

Explanation of Responses:

- These shares include the following Restricted Stock Units (RSUs) granted under the Amgen Inc. 2009 Equity Incentive Plan: 81 RSUs which will vest on 4/27/2022; 614 RSUs which will vest on 4/27/2022; 283 RSUs which vest in installments of 139 on 5/3/2022 and 144 on 5/3/2023; 401 RSUs which vest in two installments of 132 on 5/5/2022 and 5/5/2023 and one installment of 137 on 5/5/2024; 392 RSUs which vest in two installments of 129 on 4/30/2023 and on 4/30/2024 and 134 on 4/30/2025; and 350 RSUs which vest in two installments of 175 on 11/5/2022 and 11/5/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
- These shares include 157 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's invested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
- 1,524 of these non-qualified stock options have vested and are exercisable.
- 2,069 of these non-qualified stock options have vested and are exercisable.
- 1,201 of these non-qualified stock options have vested and are exercisable and 620 of these options will vest and become exercisable on 4/27/2022.
- 1,218 of these non-qualified stock options have vested and are exercisable and the remaining options will vest and become exercisable in installments of 1,218 on 5/3/2022 and 1,256 on 5/3/2023.
- These non-qualified stock options will vest and become exercisable in two installments of 1,110 on 5/5/2022 and 5/5/2023 and one installment of 1,145 on 5/5/2024.
- These non-qualified stock options will vest and become exercisable in three installments of 1,123 on 4/30/2023, 1,124 on 4/30/2024 and 1,158 on 4/30/2025.

/s/ Derek Miller

03/17/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Power of Attorney

Know all men by these presents, that the undersigned hereby constitutes and appoints each of Dennis Yai and Andrea A. Robinson, signing singly, the undersigned's true and lawful attorney-in-fact to execute for and on behalf of the undersigned Forms 3, 4 and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder, as may be required as a result of the undersigned's position as an officer and/or director of Amgen Inc. (the "Company").

The undersigned hereby grants to each such attorney-in-fact full power and authority to execute such Forms 3, 4 and 5 as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 3rd day of March, 2022.

/s/ Derek Miller
Name: Derek Miller